Payment overview · 2025
General Payments
$718.84
39 reported records · 12 companies
Healthcare provider profile · identity verified
Daniel E Hardy, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LOS BANOS, CA · NPI 1689679045
Verified facts
What the public records show
CMS Open Payments records show Daniel E Hardy, M.D. received $718.84 in general payments during 2025 across 39 reported records.
Lilly USA, LLC accounted for 43.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Rexulti, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $312.45 | 43.5% | 22 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $87.18 | 12.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $78.85 | 11.0% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.19 | 7.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $49.62 | 6.9% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $25.97 | 3.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.35 | 3.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.77 | 3.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.41 | 2.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.39 | 2.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.81 | 2.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.85 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $718.84 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $291.83 | 20 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $87.18 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $78.85 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $78.85 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.19 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $49.62 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $25.97 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.35 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.77 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.39 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.85 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $10.46 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $10.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 69 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 41 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 45 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
45 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
69 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 301 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 232 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 227 | 66 |
| Gabapentin | Gabapentin | 175 | 43 |
| Losartan Potassium | Losartan Potassium | 167 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 153 | 30 |
| Metformin Hcl | Metformin Hcl | 126 | 36 |
| Furosemide | Furosemide | 125 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 117 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 107 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 38 |
| Omeprazole | Omeprazole | 98 | 33 |
| Ozempic | Semaglutide | 97 | 20 |
| Farxiga | Dapagliflozin Propanediol | 96 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 89 | 26 |
| Carvedilol | Carvedilol | 83 | 20 |
| Glipizide | Glipizide | 72 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 71 | 27 |
| Jardiance | Empagliflozin | 69 | 19 |
| Trulicity | Dulaglutide | 68 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 64 | 14 |
| Lisinopril | Lisinopril | 62 | 26 |
| Tramadol Hcl | Tramadol Hcl | 59 | 15 |
| Morphine Sulfate Er | Morphine Sulfate | 55 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 16 |
| Allopurinol | Allopurinol | 50 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 50 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | 17 |
| Trazodone Hcl | Trazodone Hcl | 48 | 13 |
| Simvastatin | Simvastatin | 45 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | 14 |
| Eliquis | Apixaban | 44 | 12 |
| Lorazepam | Lorazepam | 44 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 44 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 43 | 11 |
| Bupropion Xl | Bupropion Hcl | 41 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 17 |
| Mounjaro | Tirzepatide | 41 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 40 | suppressed |
| Meloxicam | Meloxicam | 39 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 38 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | 11 |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | suppressed |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 33 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Potassium Chloride | Potassium Chloride | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 24 | suppressed |
| Famotidine | Famotidine | 24 | suppressed |
| Fentanyl | Fentanyl | 24 | suppressed |
| Clotrimazole | Clotrimazole | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | 11 |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 16 |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 20 | suppressed |
| Trospium Chloride | Trospium Chloride | 20 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Rexulti | Brexpiprazole | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 13 |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Prednisone | Prednisone | 16 | 11 |
| Azithromycin | Azithromycin | 15 | 14 |
| Celecoxib | Celecoxib | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Tadalafil | Tadalafil | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Viberzi | Eluxadoline | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Fanapt | Iloperidone | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $718.84 · 39 records | Lilly USA, LLC | CAPVAXIVE, Dexcom G6 Transmitter, GARDASIL 9, JARDIANCE, Korlym, Leqembi, M-M-R II, MOUNJARO, NURTEC ODT, REPATHA, REXULTI, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VAXNEUVANCE, Veozah, XIFAXAN, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error